Caribou's vispa-cel shows 82% response rate in second-line lymphoma trial

Caribou Biosciences reported long-term data for vispa-cel CAR-T therapy showing 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patients, with a well-tolerated safety profile. The results support the company's planned ANTLER-3 phase 3 pivotal trial and position vispa-cel as a competitive off-the-shelf cell therapy option.